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Nitric oxide (NO) is a reactive endogenous molecule
with multiple functions and its cellular signaling
activity is mainly mediated by activation of
the soluble isoform of guanylyl cyclase, a hetero-
dimeric (a/b) hemeprotein. The expression of the
NO-sensitive soluble isoform of guanylyl cyclase was
studied in various cultured melanocytic cells by
measuring the accumulation of guanosine 3¢,5¢-cyclic
monophosphate in the presence and absence of NO
donors. Here we report that 3-morpholino-sydnoni-
mine, a donor of NO redox species, and (Z)-1-[2-
(2-aminoethyl)-N-(2-ammonioethyl)amino]diazen-1-
ium-1,2-diolate, a direct NO donor, induced a 20-
fold increase in intracellular guanosine 3¢,5¢-cyclic
monophosphate in nonmetastatic melanoma cells
and normal melanocytes in culture that could be
related to cellular melanin content in a concentra-
tion-dependent manner. The increased intracellular
guanosine 3¢,5¢-cyclic monophosphate was due to
stimulation of the activity of soluble guanylyl cyclase
as such increase was completely abolished by using a
speci®c inhibitor of soluble guanylyl cyclase. The
involvement of functional soluble guanylyl cyclase
was further con®rmed by the presence of a1 and b1
subunits in these cells at both mRNA and protein
levels. In contrast, none of the NO donors induced
guanosine 3¢,5¢-cyclic monophosphate production in
metastatic melanoma cells, which could be attributed
to the absence of the b1 subunit that is essential for
catalytic activity of the soluble isoform of guanylyl
cyclase. Metastatic melanoma cells produced higher
levels of intracellular guanosine 3¢,5¢-cyclic mono-
phosphate in response to natriuretic peptides than
other cell types, however, due to upregulation of
membrane-bound guanylyl cyclase activities, but
they are less pigmented or unpigmented. The pre-
sent ®nding suggests that NO signaling in association
with melanogenesis is dependent on the soluble
isoform of guanylyl cyclase, whereas absence of
soluble guanylyl cyclase but the presence of
membrane-bound guanylyl cyclase correlates with
the metastatic behavior of melanoma cells. Key words:
human/melanogenesis/natriuretic peptides/nitric oxide
donors. J Invest Dermatol 116:409±416, 2001
N
itric oxide (NO) plays a key role in physiologic as
well as pathophysiologic processes, including
in¯ammation and skin cancer (Schmidt and Walter,
1994; Bruch-Gerharz et al, 1998). It is synthesized
by NO synthase (NOS) on conversion of L-
arginine to citrulline. Three isoforms of NOS were identi®ed by
cloning of their complementary and genomic DNAs (FoÈrstermann
et al, 1991). One isoform is largely but not exclusively expressed in
neuroneal tissues (nNOS), whereas another is predominantly found
in endothelium (eNOS). Generally, nNOS and eNOS are
considered constitutive enzymes. The other isoform is an inducible
type (iNOS) that is absent in most cells under normal conditions.
The expression of iNOS is only evident in several cell types by
stress signals from the immune and in¯ammatory systems (Bredt
and Snyder, 1994; Nathan and Xie, 1994).
Once NO is produced, it has diverse biologic functions. NO
binds to the heme prosthetic group of the soluble guanylyl cyclase
(sGC), a heterodimeric (a/b) protein (Ignarro, 1990), leading to
increases in the formation of guanosine 3¢,5¢-cyclic monophosphate
(cGMP) and in downstream phosphorylation of several proteins
that are associated with many physiologic processes, such as
vasodilation, inhibition of platelet aggregation, and regulation of
neural activity (Bredt and Snyder, 1989; Moncada et al, 1991;
Schmidt and Walter, 1994). On the other hand, it has been shown
in human melanocytic cells that ultraviolet B radiation, a
physiologic stimulus of melanogenesis, acts through the NO/
cGMP signal transduction pathway, and a constitutive isoform of
NOS is involved in this process (Romero-Graillet et al, 1996).
Additionally, iNOS was recently reported to be also constitutively
expressed in human melanocytes, and a role of a-melanocyte-
stimulating hormone in the regulation of NO production in
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melanocytes by modulating the induction of iNOS has been
suggested (Tsatmali et al, 2000). Moreover, NO is also regarded as a
cellular toxin as it can act cytostatically and/or cytotoxically for
tumor cells as well as various pathogens (Nussler and Billiar, 1993;
Nathan and Xie, 1994; Vouldoukis et al, 1995). Cytostatic effects of
NO may occur either directly by NO-producing cells or indirectly
via induction of NO production in tumor-in®ltrating macrophages
(Stuehr and Nathan, 1989), and NO also plays a facilitatory role in
tumor growth through neovascularization (Jenkins et al, 1995). It
has been suggested that the protumor and antitumor actions of NO
might depend on its local concentration (Jenkins et al, 1995).
Interestingly, Dong et al (1994) demonstrated an inverse correlation
between the production of endogenous NO and the metastatic
behavior of murine K-1735 melanoma cells. Moreover, over-
expression of recombinant iNOS in K-1735 cells was shown to be
associated with apoptosis (Xie et al, 1995). Finally, an inverse
correlation between iNOS expression in regional human melano-
ma metastasis and a tumor's metastatic potential was also recently
reported (Tschugguel et al, 1999).
The diverse cellular effects of NO are regarded as due to its
signaling activity, which is mediated mainly by the activation of
sGC. In contrast to the key role of sGC in NO signaling, the
membrane-bound isoforms of guanylyl cyclase (GC) GC-A,
GC-B, and GC-C serve as receptors for speci®c natriuretic
peptides and enterotoxins. For instance, GC-A binds atrial
natriuretic peptide (ANP) and brain natriuretic peptide (BNP),
GC-B preferentially binds C-type natriuretic peptide (CNP), and
the intestinal isoform GC-C binds the heat-stable enterotoxins
(STa) of Escherichia coli as well as their endogenous homologs
guanylin/uroguanylin (Hambra et al, 1993; Garbers and Lowe,
1994). Although the natriuretic peptides are generally thought to
participate in regulation of blood pressure as well as in water and
electrolyte homeostasis, several studies have shown that ANP and
CNP may modulate proliferation in endothelial, vascular smooth
muscle, and mesangial cells (Lewicki and Potter, 1995). Finally,
recent data demonstrated a large decrease in guanylin expression in
colorectal adenocarcinomas and colon cancer cell lines (Cohen et al,
1998), and GC-C expression has been associated with colorectal
cancer micrometastasis in extra-intestinal tissues (Waldman et al,
1998).
As sGC plays a key role in NO signaling, in this study we
compared the regulation of cGMP production in cultured human
melanocytes and various melanoma cell lines with the use of a
number of NO donors, different natriuretic peptides, and
enterotoxins. Our results show that a functional sGC expression
is absent in metastatic melanoma cells, as the enzymatic activities of
the natriuretic peptide-sensitive membrane-bound isoforms GC-A
and GC-B appear to be upregulated in highly metastatic cells.
MATERIALS AND METHODS
Culturing cell lines The melanoma cell lines used in this investigation (a
kind gift from Prof. Dr. G. van Muijen, Department of Pathology,
Nijmegen University, The Netherlands) differ in their capacity to form
metastasis after subcutaneous inoculation into nude mice (Van Muijen et al,
1991; Danen et al, 1993). The human melanoma cell lines 1F6 (pigmented)
and 530 (nonmetastatic), M14 (pigmented) and Mel57 (sporadically
metastatic), BLM and MV3 (highly metastatic) were cultured using
Dulbecco's modi®ed Eagle's medium (DMEM), supplemented with 10%
(vol/vol) heat-inactivated fetal bovine serum and antibiotics as described
elsewhere (Danen et al, 1993). The normal human melanocyte cultures,
established from individual foreskins of different grades of pigmentation,
were maintained essentially according to the method described previously
by us (Le Poole et al, 1993). The melanocytes were used in passages 3±8
(P3±8) and the different experiments were performed only with cells from
the same passage number.
Preparation of cytosolic melanocyte fractions For analyses of sGC,
melanocytes [(40±50) 3 106 cells] were harvested by scraping in ice-cold
cell-lysis buffer [10 mM HEPES, pH 7.4, 150 mM NaCl, 5 mM
ethylenediaminetetraacetate (EDTA), 10 mg per ml aprotinin, 10 mM E-
64, 10 mg per ml phenylmethylsulfonyl ¯uoride, 1 mM dithiothreitol
(DTT)] in a ®nal volume of 5 ml. Subsequently, cells were
homogenized, sonicated, and centrifuged at 100,000 3 g for 60 min
(4°C), and the supernatant fraction was kept at 4°C until assayed. For
storage, fractions were brought to a ®nal concentration of 50% (vol/vol)
glycerol and kept at ±20°C. Protein concentrations were determined by the
Bradford method (Bradford, 1976) using bovine serum albumin (BSA) as
standard.
Determination of GC activity GC activity was measured by
conversion of guanosine 5¢-triphosphate (GTP) to cGMP at 37°C for
10 min essentially as described previously by us (Ivanova et al, 1990).
Brie¯y, GC activity was measured in 50 mM triethanolamine
hydrochloride buffer, pH 7.4, containing 1 mM GTP, 1 mM 3-isobutyl-
1-methylxanthine (IBMX) as a phosphodiesterase inhibitor, 3 mM Mg2+ or
Mn2+ as divalent metal ions, 50 mg per ml creatine phosphokinase (10 units
per ml), and 5.5 mM creatine phosphate. For analyzing sGC activity 1 mM
DTT was added to the buffer solution. Assays were initiated by adding
3-morpholino-sydnonimine (SIN-1, kindly provided by Dr. Grewe,
Hoechst AG, Frankfurt, Germany) or DETA NONOate (or DETA/
NO, Alexis Biochemicals, GruÈnberg, Germany) as NO donors (20 ml) and
cell extract (20 ml) to the buffer solution for 10 min at 37°C in a ®nal
volume of 100 ml per sample. Reactions were stopped by addition of
boiling 30 mM EDTA and resultant cGMP was analyzed by a
radioimmunoassay procedure as described in detail elsewhere (Ivanova
et al, 1990). Reaction rates were constant over the incubation period (not
shown). The GC activities are expressed as pmol cGMP per mg protein
per min.
Measurement of cGMP levels in melanocytes For subsequent
experiments, melanocytes were seeded onto six-well culture plates
(Falcon, Becton and Dickinson, Heidelberg, Germany) at a density of
0.5 3 106 or 1 3 106 cells per well and were grown for 24 h in the
appropriate medium as described previously by us (Ivanova et al, 1997).
After washing with phosphate-buffered saline (PBS), cells were maintained
for 4 h in a mitogen-de®cient medium (1 ml per well) containing phenol-
red-free DMEM supplemented with 0.25% BSA, 10 mM HEPES, pH 7.4
(DMEM-BSA), before stimulation with GC activators. Then melanocytes
were preincubated for 15 min with 0.1 mM IBMX. For testing the
activation of sGC, melanocytes were treated for 5 min with SIN-1
(0.01±1 mM) (Feelisch et al, 1989; Ivanova et al, 1993). Denitrosylated
solutions of SIN-1 (which contain the inactive byproducts) as controls were
obtained as described elsewhere (Ivanova et al, 1997). For activation of
GC-A, GC-B, and GC-C the melanocytes were incubated for 15 min with
human a-ANP1±28, BNP32, CNP22, guanylin (Peninsula Lab., St. Helens,
U.K.), and STa toxin (Sigma, St. Louis, MO) in the range of 0.001±1 mM.
DMEM-BSA medium without addition of peptides was used as control.
The time for incubation and the concentration range of response with less
than 10% of cell toxicity were chosen following time-course and dose-
dependent experiments. Cell viability was assessed by trypan blue
exclusion. Protein content was determined by the method of Lowry et al
(1951) with BSA as standard. Melanin content was measured as described
by Lee et al (1972) with synthetic melanin (Sigma, Deisenhofen, Germany)
as standard. Values are expressed in mg melanin per 106 cells.
For measurement of extracellular cGMP, the DMEM-BSA medium was
removed at indicated times and stored at ±20°C until assayed. For
measurement of intracellular cGMP, 1 ml of ice-cold trichloroacetic acid
(5%, wt/vol) was added to the adherent cells. The resulting resuspensions
were then centrifuged (1500 3 g, 15 min) and pellets were resuspended in
1N NaOH for protein estimation. After washing the supernatants with
water-saturated ether, samples were lyophilized, resuspended in sodium
acetate buffer, pH 4.0, and stored at ±20°C until assayed. Concentrations of
cGMP were determined by radioimmunoassay. All samples were measured
in duplicate. Results are expressed as pmol cGMP per mg protein.
Western blotting For western blotting, cytosolic fractions (100,000 3 g)
of the investigated melanoma cells (23 mg each) were subjected to sodium
dodecyl sulfate polyacrylamide gel electrophoresis [SDS-PAGE; 10%
(wt/vol) gels] and electroblotted to nitrocellulose membranes (Schleicher
& Schuell, Dassel, Germany) (Laemlli, 1970). Blots were blocked overnight
at 4°C in PBS (136 mM NaCl, 2.7 mM KCl, 8.1 mM Na2HPO4, 1.5 mM
KH2PO4, pH 7.5) containing 3% (wt/vol) ovalbumine (Sigma,
Deisenhofen, Germany). Subsequently, the nitrocellulose sheets were
incubated for 2 h at room temperature with an anti-sGC polyclonal
antiserum that recognizes the human a1 and b1 subunits (Alexis
Biochemicals, GruÈnberg, Germany; dilution 1:1000) or an antiserum
against the human b1 subunit (kindly provided by Prof. Dr. D. Koesling,
Pharmacy Department, Bochum University, Germany; dilution 1:1000) in
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PBS containing 1% (wt/vol) ovalbumine and 0.025% Tween 20. After
three washes with PBS containing 0.1% Triton X 100 (PBST), the blots
were incubated for 60 min at room temperature with a goat antirabbit
alkaline-phosphatase-conjugated secondary antibody (Boehringer,
Mannheim, Germany; dilution 1:1250). After three washes with PBST,
bands were visualized with 0.01% (wt/vol) NBT (nitro blue tetrazolium
chloride/5-bromo-4-chloro-3-indol-phosphate, Sigma, Deisenhofen,
Germany), 0.05% (vol/vol) BCIP (5-bromo-4-chloro-3-
indolylphosphate, Biomol Feinchemikalien, Hamburg, Germany), and
0.4 M MgCl2 in 1.5 M Tris-HCl, pH 9.6, at 38°C.
RNA extraction and reverse transcriptase±polymerase chain
reaction (RT-PCR) Total RNA was isolated from melanocyte
cultures by the RNA-Clean System (Angewandte Gentechnologie
Systeme, Heidelberg, Germany) following the manufacturer's instructions
and was quanti®ed by absorbance at 260 nm. RNA samples were incubated
with 1 ml RNase-free DNase (Boehringer; 10 units) per mg of total RNA
for 30 min at 37°C to digest traces of genomic DNA. After reverse
transcription of 1 mg of total RNA by speci®c priming and SuperScript II
RNase H± Reverse Transcriptase (Gibco BRL Life Technologies,
Karlsruhe, Germany; 10 units), the resultant single-stranded cDNA was
subjected to PCR for sGC, GC-B, and GC-A. PCR were initiated by
adding gene-speci®c primers (20 pmol each) to 2 ml cDNA in 50 ml PCR
buffer, pH 8.7 (Qiagen, Hilden, Germany), containing 1.5 mM MgCl2 and
0.2 mM each of the four dNTPs, HotStar Taq DNA polymerase (Qiagen;
2.5 units), and with or without addition of Q-solution (Qiagen)
under mineral oil. The following speci®c primers were used: for human
sGC-b3 (later renamed human b1, Zabel et al, 1998) subunit, 5¢-
CGTGTCCTGGGCTCTAA-3¢ (sense) and 5¢-ACCACTAGGTC-
CCGGTC-3¢ (antisense), yielding a 430 bp product, and for human a3
(later renamed a1, Zabel et al, 1998) subunit, 5¢-AACGAGTCT-
TCAGAGGAGG-3¢ (sense) and 5¢-AGAAGGGTACTGAAGCTGT-3¢
(antisense), yielding a 424 bp product, as described elsewhere
(Papapetropoulos et al, 1996); for GC-B, 5¢-GAGACGATTG-
GGGATGCTTA-3¢ (sense) and 5¢-TTGGTGGTAGAGGAGAGA-
TGGAT-3¢ (antisense), yielding a 302 bp product (a kind gift from
Dr. J. R. Hirsch, WestfaÈlische Wilhelm-UniversitaÈt MuÈnster, Germany);
and for GC-A, 5¢-CTTGGGGAGAGGGGGAGTAGCAC-3¢ (sense) and
5¢-GGGGTCGGGGGAGCAGGTAT-3¢ (antisense), yielding a 490 bp
product (kindly provided by Dr. J. R. Hirsch). After an initial 15 min
denaturation at 95°C, 30 or 35 cycles of PCR ampli®cation were then
carried out (93°C for 45 s or 1 min, 57°C for 1 min, 72°C for 1 min), with a
®nal extension at 72°C for 10 min. The PCR products (18 ml) were
analyzed on 1.5% agarose gels and visualized using ethidium bromide. To
further test the speci®city of the ampli®ed product, some PCR products
were analyzed on the automated ABI 377HAT sequencer (Applied
Biosystems, Weiterstadt, Germany) by GATC (Konstanz, Germany).
Data presentation Concentration-response curves were ®tted to the
experimental results using a computer program (Jandel Scienti®c, San
Rafael, CA) and the relationship E = Emax/[1 + (K/x)n], where E is the
effect of the NO donor on the intracellular cGMP production in
melanocytes, Emax is the maximum effect, x is the concentration of the
NO donor, K is the concentration of the NO donor giving 50% elevation
(EC50) of cGMP levels, and n is the Hill coef®cient. Results are shown as
means 6 SEM. Means were analyzed by unpaired Student's t test using
Sigma plot (Jandel Scienti®c). p-values of less than 0.05 were considered as
indicating signi®cant differences.
RESULTS
Expression of sGC as a target for NO signaling in melano-
cytic cell lines
Differential effects of NO donors on cGMP accumulation in normal human
melanocytes and melanoma cell lines First, we studied the effects of
NO on the cGMP formation in intact human melanocytic cells as a
measure of catalytically active sGC. For this purpose, melanocytes
were treated in the absence and presence of IBMX as an inhibitor
of phosphodiesterase for 5 min with increasing concentrations of
the NO donor SIN-1 (0.01±1 mM). The NO donor elevated
intracellular cGMP formation in cultured melanocytes and
nonmetastatic melanoma cell lines in a dose-dependent manner,
whereas extracellular cGMP levels were not affected (data not
shown). The effects of SIN-1 on the intracellular cGMP formation
in relation to cellular melanin content are presented in Fig 1. It can
been seen that SIN-1 elevated intracellular cGMP levels by
1815% 6 218% in highly pigmented Mf9055 (27.2 6 3 mg melanin
per 106 cells) (Fig 1A) and by 829% 6 68% in nonmetastatic and
pigmented 1F6 (25.3 6 4 mg melanin per 106 cells) (Fig 1B). cGMP
levels of less pigmented melanocytes Mf9039 (3.7 6 0.3 mg melanin
per 106 cells) and unpigmented and nonmetastatic 530 cells were
elevated only 2- to 3-fold over basal levels by SIN-1. In addition,
denitrosylated solutions of SIN-1 (which contain the inactive
byproducts) as controls were not active. These results indicate that
cultured melanocytes and nonmetastatic melanoma cell lines
express a functional sGC that can be related to melanogenesis as
evident by their melanin content.
On the other hand, we found that SIN-1 did not elevate cGMP
levels in metastatic melanoma cell lines (Fig 1B), suggesting
absence of functional sGC expression in these cells. We also
compared the effect of SIN-1 on the extent of cGMP formation of
the metastatic clone of 1F6 (1F6-m) to that in the nonmetastatic
1F6 cells (Fig 2). SIN-1 increased cGMP levels about 8-fold (basal,
1.4 6 0.2; SIN-1, 11.9 6 1.2 pmol per mg protein; n = 12) in the
nonmetastatic cells. This effect was reversed by preincubations of
the cells for 30 min with 10 mM 1H-[1,2,4]oxadiazolo[4,3-
a]quinoxalin-1-one (Tocris Cookson, Bristol, U.K.), a speci®c
inhibitor of sGC (Schrammel et al, 1996), indicating that such
increase was due to stimulation of sGC activity (Fig 2A). Finally,
SIN-1 did not elevate cGMP levels in the metastatic 1F6-m cells
(Fig 2B), again indicating absence or suppression of sGC activity in
metastatic melanoma cells.
NO stimulates sGC activity in cytosolic fractions of nonmetastatic
melanocytes but is not effective in metastatic melanoma cells To con®rm
Figure 1. NO is functionally active in human
normal melanocytes and nonmetastatic mel-
anoma cells. Intracellular cGMP levels (h) fol-
lowing incubation with SIN-1 (1 mM) and the
melanin content (j) in cultured human melano-
cytes (A) and in melanoma cell lines (nonmeta-
static: 530, 1F6; sporadically metastatic: M14,
Mel57; highly metastatic: MV3, BLM) (B) were
determined as described in Materials and Methods.
Results (pmol cGMP) are normalized to protein
content (mg) and are expressed as percent induc-
tion compared with the unstimulated control mel-
anocytes (100%). Data present means 6 SEM of
four replicates of four independent experiments.
Values of melanin content are means 6 SEM of
triplicates of three independent experiments. All
values presented in (A) are signi®cantly different
from controls. * p < 0.05 vs control; ** p < 0.05
vs unpigmented BLM.
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the differential effect of NO on intracellular cGMP accumulation
in melanocytic cells, we directly investigated the effects of different
NO donors on sGC catalytic activity in cytosolic fractions obtained
from nonmetastatic 1F6 (pigmented) cells and metastatic Mel57,
M14 (pigmented), and metastatic BLM cells. As shown in Fig 3,
DETA/NO, a direct donor of NO, and SIN-1 as a donor of NO
redox species increased sGC activities in nonmetastatic 1F6 cell
fractions in a dose-dependent manner. At maximal concentration,
SIN-1 and DETA/NO (1 mM) stimulated sGC activity of 1F6 cells
10-fold (basal, 0.24 6 0.02; DETA/NO, 2.43 6 0.15 pmol cGMP
per mg per min; n = 6) in the presence of 3 mM Mg2+ and 6-fold
(basal, 0.24 6 0.02; SIN-1, 1.45 6 0.4 pmol cGMP per mg per
min; n = 6) in the presence of 3 mM Mn2+, respectively. As
expected, SIN-1 and DETA/NO were unable to stimulate cGMP
production in supernatant fractions of the investigated metastatic
cells (data not shown), indicating absence of functional sGC in
metastatic melanoma cells.
Absence of functional sGC is due to the lack of b1 subunit expression of
sGC in metastatic melanoma cells As sGC exists as a heterodimeric
heme-containing cytosolic enzyme (Gerzer et al, 1981) comprising
an a subunit (~80 kDa) and a b subunit (~70 kDa), we further
studied the expression of these subunits at the protein levels. As
revealed by SDS-PAGE analyses (Fig 4A), a 67 kDa protein band
was found in nonmetastatic 1F6 cells and cultured human
melanocytes (data not shown), but not in metastatic melanoma
cell lines. The western blot analyses demonstrated that this band
was recognized by sGC polyclonal antisera against the a1 and b1
subunits (Fig 4B) and by speci®c antiserum against the b1 subunit
(data not shown), indicating expression of the b1 protein in these
cells. The polyclonal antiserum additionally detected a ~78 kDa
band in the soluble fractions of melanoma cells (Fig 4B) that
probably represents the larger a1 subunit of sGC. Therefore, it
appears that all investigated metastatic melanoma cell lines lack the
b1 protein of sGC.
In order to con®rm the absence of b1 subunits in metastatic
melanoma cells, we further studied the expression of sGC subunits
at mRNA levels. As revealed by RT-PCR analyses, nonmetastatic
1F6 cells and cultured human melanocytes expressed speci®c PCR
products for both a1 (Fig 5A) and b1 (Fig 5B) subunits of sGC.
These speci®c products were not detected in the absence of reverse
transcriptase (negative control) indicating that they were due to the
speci®c cDNA ampli®cation. As expected, speci®c PCR products
for the a1 subunit (Fig 5A) were detected in all investigated
melanoma cell lines, and none of the metastatic melanoma cells
expressed the respective product for the b1 subunit (Fig 5B). The
sequences of the PCR fragment for a1 (nucleotide residues 601±
1032, i.e., a 425 bp segment of the corresponding 430 bp DNA
fragment; GenBank X66534) and b1 (nucleotide residues 350±774,
i.e., a 421 bp segment of the corresponding 424 bp DNA fragment;
GenBank X66533) subunits of sGC ampli®ed from 1F6 cells were
found to be correct (sequence traces not shown). Therefore, it
Figure 2. Differential effect of SIN-1 on cGMP accumulation in
nonmetastatic and metastatic 1F6 melanoma cells. Production of
cGMP in nonmetastatic 1F6 cells and in 1F6-m, a metastatic clone of 1F6
cells, in the absence (h) and in the presence of SIN-1 (r, 0.1 mM; j,
1 mM) is shown in (A) and (B), respectively. The SIN-1-induced increase
in intracellular cGMP levels was reversed in the presence of 10 mM 1H-
[1,2,4]oxadiazolo[4,3-a]quinoxalin-1-one (ODQ), a selective inhibitor of
sGC activity. Data present the means 6 SEM of four replicates of three
independent experiments. * p < 0.05 vs control.
Figure 3. Dose-dependent stimulation of sGC activity in cytosolic
fractions of nonmetastatic 1F6 cells by different NO donors. The
sGC activity was determined as described in Materials and Methods after
stimulation with SIN-1 (open symbols) as a donor of NO redox species or
DETA/NO (®lled symbols) as a direct donor of NO in the presence of
3 mM Mn2+ (n/m) or 3 mM Mg2+ (s/d). Data present means 6 SEM of
duplicates of three independent experiments.
Figure 4. Absence of human b1 sGC subunit expression in meta-
static melanoma cell lines. (A) The 100,000 3 g soluble fractions (23 mg
of proteins per lane) of nonmetastatic and metastatic melanocyte
homogenates were analyzed by SDS-PAGE [10% (wt/vol)] and Coomassie
Blue protein staining. (B) The soluble fractions were analyzed by protein
immunoblotting using a polyclonal antiserum to human a1 and b1 subunits.
Bands were visualized with NBT/BCIP. In nonmetastatic 1F6 cells two
bands of ~78 kDa and 67 kDa were detected that represent the a1 and b1
subunits. By contrast in all investigated metastatic melanoma cells the
67 kDa band was absent. For comparison the enzyme puri®ed from
supernatant of recombinant sGC a1 and b1 overexpressing Sf9 insect cell
cultures is shown (K). Negative controls for BLM (1) and 1F6 (2) were
similarly stained by omitting the primary antibody to determine back-
ground immunoreactivities. Results shown are representative of three
repeat analyses.
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could be concluded that the absence of functional sGC in
metastatic melanoma cell lines is due to absence of mRNA coding
for the b1 subunit of sGC.
Expression of membrane-bound GC isoforms in
melanocytic cells
Metastatic melanoma cell lines produce higher levels of intracellular cGMP
than nonmetastatic melanocytes in response to natriuretic peptides To
compare the cGMP elevation following sGC activation to that
following activation of the membrane-bound isoforms, melano-
cytic cells were incubated for 15 min with the respective
membrane-bound GC activators in the presence of IBMX. The
activator of GC-A, ANP (1 mM), stimulated cGMP accumulation
up to 25-fold over basal levels in metastatic melanoma cell lines
(Fig 6A). ANP also induced increases in extracellular cGMP levels
in melanoma cells (data not shown). Increases with 1 mM BNP, also
an activator of GC-A, were smaller in magnitude than those seen
with 1 mM ANP (data not shown). The corresponding CNP-
induced elevations (indicating activation of GC-B) of intracellular
cGMP levels are shown in Fig 6(B). The increase in cGMP in
response to CNP was signi®cantly higher in metastatic melanoma
cells (BLM, 7026% 6 862%; MV3, 5500% 6 448%), which are
unpigmented, compared with that in nonmetastatic pigmented 1F6
cells (589% 6 84% over baseline). Increases with BNP, however,
were lower than those seen with ANP. The activators of GC-C,
STa toxin (1 mM), and guanylin (1 mM) produced minor elevations
in intracellular cGMP levels (approximately 2-fold over basal levels)
Figure 5. Representative analysis of RT-PCR
products of human sGC subunits by agarose
gel electrophoresis stained with ethidium
bromide. Total RNA was reverse transcribed and
ampli®ed for 35 cycles. (A) Ampli®cations of the
human a1 subunit of sGC (424 bp) in melanoma
cell lines. M represents 100 bp ladder; + and ±
signs indicate presence and absence, respectively,
of reverse transcriptase from the reaction mixture.
(B) Ampli®cations of the human b1 subunit of
sGC (430 bp) in normal human melanocytes (e.g.,
Mf9420) and melanoma cell lines. M represents
100 bp ladder; 1 and 2 indicate the absence of re-
verse transcriptase from the reaction mixture with
1F6 and Mf9420; 3 shows the absence of cDNA
in the PCR reaction mixture.
Figure 6. Upregulated membrane-bound GC-
A and GC-B activities in highly metastatic
melanoma cell lines. The effects of ANP (h) as
a ligand of GC-A and CNP (j) as a ligand of
GC-B on cGMP levels of cultured human mela-
nocytes (NHMs) nonmetastatic 530, 1F6; sporadi-
cally metastatic M14, Mel57; and highly metastatic
MV3, BLM cells are shown in (A) and (B), re-
spectively. Results (pmol cGMP) are normalized
to protein content (mg) and are expressed as per-
cent induction compared with the unstimulated
control melanocytes (100%). Data present means
6 SEM of triplicates of four independent experi-
ments. All values presented in (A) are signi®cantly
different from controls. * p < 0.05 vs. control.
Figure 7. Dose-dependent stimulation of in-
tracellular cGMP formation in highly meta-
static melanoma cell lines by natriuretic
peptides and STa toxin. (A) cGMP accumula-
tion in BLM (open symbols) and (B) MV3 cells
(®lled symbols) following stimulation with different
activators of the membrane-bound GC isoforms
[CNP (h/j), ANP (e/r), BNP (,/.), and
STa toxin (s/d)]. Data present means 6 SEM of
four replicates of three independent experiments.
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in all investigated melanocytes (data not shown) suggesting low
activity of GC-C. In addition, the concentration-response curves of
the effects of the membrane GC activators on intracellular cGMP
production in highly metastatic BLM and MV3 cells are shown in
Fig 7. CNP was the most potent of the natriuretic peptides studied.
After 15 min of incubation, intracellular cGMP levels were
increased by 1 mM CNP from a control level of 1.0 6 0.2 to
70.6 6 7.6 pmol per mg protein (n = 12) in highly metastatic BLM
(Fig 7A) and to 52.1 6 5.7 pmol per mg protein (n = 12) in MV3
cells (Fig 7B), respectively. The apparent EC50 was at about
0.1 mM CNP for BLM cells and at about 0.3 mM CNP for MV3
cells. ANP at 1 mM concentrations increased cGMP formation up
to 23.4 6 2.6 pmol per mg protein (n = 12, p < 0.001) in BLM and
up to 19.7 6 2.2 pmol per mg protein (n = 12, p < 0.001) in MV3
cells. Increases with BNP were lower than those seen with ANP.
STa toxin and guanylin (data not shown) did not alter intracellular
cGMP in the cells signi®cantly. The order of potency
CNP > ANP > BNP » STa toxin is consistent with type B > type
A » type C membrane GC subclasses being present in the highly
metastatic BLM and MV3 cell lines. Together, these results indicate
that metastatic melanoma cells that are insensitive to NO produce
higher cGMP levels than melanocytes and nonmetastatic pheno-
types in response to ANP and CNP but in fact are less pigmented
or unpigmented.
RT-PCR analysis of the expression of mRNA for GC-A and GC-B in
melanocytic cells In order to con®rm further the absence or
presence of membrane-bound GC isoforms in melanocytic cells
we investigated the expression of GC-A and GC-B at the mRNA
levels. As revealed by RT-PCR analyses a speci®c PCR product
for GC-A of a 490 bp was detected in all investigated melanocytes
(Fig 8A). In metastatic BLM and MV3 cells a 590±610 bp band was
present, however (data not shown). This RT-PCR product may
represent a so far unknown isoform of GC-A expressed in these
cells or may be an artefact. Also, a speci®c PCR product for GC-B
of 302 bp was detected in highly metastatic BLM and MV3, and
nonmetastatic 1F6 cells, but also in normal melanocytes (Fig 8B).
The sequences of the PCR fragment for GC-B ampli®ed from
BLM cells (nucleotide residues 3366±3667, i.e., a 296 bp segment
of the corresponding 302 bp DNA fragment, GenBank L13436)
and the PCR fragment for GC-A from M14 cells (nucleotide
residues 3197±3687, i.e., a 468 bp segment of the corresponding
490 bp DNA fragment; GenBank 4505434) were found to be
correct (not shown here). These results indicate the presence of
mRNAs coding for GC-A and GC-B in melanoma cell lines but
also in normal melanocytes.
DISCUSSION
These results demonstrate that cultured human melanocytes and
nonmetastatic melanoma cell lines express predominantly sGC, a
prime target for the signaling activity of NO, which appears to be
associated with melanogenesis as evident by their melanin contents.
Our data, however, do not provide conclusive evidence of the
mechanistic aspects of the NO-sensitive isoform of GC in relation
to melanogenesis. The most important ®nding of this study is the
demonstration that metastatic melanoma cell lines lack the b1
subunit of the NO-sensitive guanylyl cyclase isoform, leading to
loss of NO sensitivity in the control mechanisms involving the
NO-sGC/cGMP pathway. On the other hand, the membrane
isoforms GC-A and GC-B, the principal targets for the signaling
activities of natriuretic peptides, are upregulated in metastatic
melanoma cells that are either less pigmented or unpigmented.
These results suggest that the differential expression of functional
GC isoforms in melanocytic cells could be correlated with
metastatic potentials.
In this study we used different NO donors, natriuretic peptides,
and enterotoxins to investigate the presence and/or absence of the
soluble and membrane-bound isoforms of GC in various melanoma
cell lines compared with normal human melanocytes in culture.
First, it could be shown that both SIN-1, a donor of NO redox
species, and DETA/NO, a direct NO donor, induced elevation of
intracellular cGMP in normal human melanocytes and nonmeta-
static melanoma cell lines, indicating that NO is the active
compound. Further, this NO-induced increase in cGMP produc-
tion can be inhibited by a speci®c GC inhibitor, demonstrating that
NO exerts its effects through the activation of sGC. Additionally,
more pigmented cultured melanocytes and nonmetastatic melano-
ma cells were more sensitive to NO-stimulated cGMP synthesis
than less pigmented nonmetastatic melanocytes. These results show
that in normal human melanocytes and nonmetastatic melanoma
cells the NO-sensitive GC isoform might be associated with
melanogenesis probably via signaling activities of NO as evident
from the studies described in the literature (Schmidt and Walter,
1994; Romero-Graillet et al, 1996).
Generally, cGMP could elicit its effects through different
pathways, involving an expanding family of regulatory proteins,
e.g., cGMP-dependent protein kinases (PKG), cGMP-binding
cyclic nucleotide phosphodiesterases, and cGMP-gated ion
channels (Schmidt and Walter, 1994). For human melanocytes in
culture, it has been shown that the NO-sGC pathway, through the
activation of PKG, is involved in ultraviolet-B-induced melano-
genesis (Romero-Graillet et al, 1996), and these authors postulated
that PKG might be important in phosphorylating some proteins
that control melanogenesis. In this respect, it can be emphasized
that tyrosine is the rate-limiting enzyme involved in melanin
synthesis and contains several phosphorylation sites in the
cytoplasmic (extra-melanosomal) domain, which are critical for
activation of the protein (Park et al, 1993, 1999). Furthermore, it
was recently shown that PKG (type II) also phosphorylates Ser19 of
6-pyruvoyl-tetrahydrobiopterin synthase (PTPS), whereby the
activity of the latter is increased 3-fold and upregulates de novo
synthesis of 6-tetrahydrobiopterin (6BH4) (Scherer-Opplinger et al,
1999; ThoÈny et al 2000). As it is known that 6BH4 directly controls
the supply of L-tyrosine for melanogenesis in the melanosome
(Schallreuter and Wood, 1999) and is also an essential cofactor/
electron donor for NO synthase (Mayer and Hemmens, 1997), it is
evident that cross-talk between NO, L-tyrosine, and 6BH4 could
Figure 8. Representative analysis of RT-PCR
products of different human membrane-
bound GC isoforms by agarose gel electro-
phoresis stained with ethidium bromide. To-
tal RNA was reverse transcribed and ampli®ed for
30 (GC-B) or 35 (GC-A) cycles. (A) Ampli®ca-
tions of the GC-A isoform (490 bp) in melanoma
cell lines and normal human melanocytes (e.g.,
Mf9505 and Mf9415). M represents 100 bp lad-
der; + and ± signs indicate presence and absence,
respectively, of reverse transcriptase from the reac-
tion. (B) Ampli®cations of the GC-B isoform
(302 bp) in melanoma cell lines and in normal hu-
man melanocytes. M represents 100 bp ladder; 1
shows the absence of cDNA in the PCR reaction
mixture.
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be important in controlling pigmentation in normal and nonmeta-
static melanocytes.
Interestingly, the NO donors SIN-1 and DETA/NO were
unable to increase cGMP production in metastatic melanoma cells
and to stimulate sGC activity in their cytosolic fraction. A reduced
cGMP accumulation in response to NO in cultured cells may be
explained by either decreased formation due to suboptimal
stimulation of sGC activity or increased degradation of cGMP.
The latter can be ruled out as all experiments were performed
under phosphodiesterase inhibition. Consequently, the former
appears to be a likely explanation. All the cultured human
melanocytes and melanoma cell lines studied presently, however,
express both nNOS and iNOS, and the expression of these enzyme
isoforms is not related to the presence or absence of catalytically
active sGC (data not shown). Indeed, for optimal NO-induced
sGC activity both the a1 and b1 subunits of the enzyme as well as
the binding of NO to the heme group are necessary. In addition,
the b1 subunit contains a porphyrin prosthetic group that is bound
to the enzyme protein with an axial ligation to a histidine residue
(Wedel et al, 1994). Therefore, it is likely that NO forms a complex
(stable) with ferrous heme as part of the multistep molecular process
of activation of sGC (Stone and Marletta, 1996; Zhao et al, 1999).
As we observed at both RNA and protein levels that metastatic
melanoma cell lines lack the b1 subunit of the NO-sensitive GC
isoform, it seems likely that metastatic melanoma cells may escape
important control mechanisms involving the NO-sGC/cGMP
pathway. In this context, it would be interesting to determine
whether the sGC/cGMP pathway is involved in NO-induced
apoptosis in melanocytic cells, as induction of high levels of NO
production in murine melanoma cell line K-1735 has been found
to be mainly associated with apoptosis (Xie et al, 1995).
In this study we further demonstrate that metastatic melanoma
cells, although lacking expression of functional sGC, produce
higher levels of cGMP in response to natriuretic peptides (ANP and
CNP) than normal and nonmetastatic melanocytes via the
upregulation of activities of membrane-bound isoforms (GC-A
and GC-B). On the other hand, mRNAs coding for GC-A and
GC-B were also detected in nonmetastatic melanocytes and normal
melanocyte cultures. The discrepancy between the presence of
membrane-bound GC protein and the absence of enzymatic
activity found in these cells re¯ects the probability that regulation of
membrane-bound GC catalytic activity occurs at post-translational
level, e.g., by phosphorylation/dephosphorylation (Garbers and
Lowe, 1994; Potter and Hunter, 1998). An alternative explanation
could be coexpression of a splice variant of GC that lacks a
functional catalytic domain as was shown for GC-B in kidney cells
(Hirsch et al, 1999). In addition, enterotoxins (STa toxin) as well as
their endogenous homolog guanylin did not signi®cantly elevate
intracellular cGMP levels in melanocytic cells, indicating absence of
functional expression of the membrane-bound GC-C isoform.
Interestingly, metastatic melanoma cells produce higher cGMP
levels than melanocytes and nonmetastatic phenotypes but in
response to ANP and CNP and not to NO. In spite of the
availability of increased intracellular cGMP the former cell types are
less pigmented or unpigmented compared with the latter group of
cells that express NO-sensitive sGC. Although it is known that
signaling activity of NO by cGMP and melanogenesis are associated
with phosphorylation of tyrosinase and PTPS through the PKG
pathway (Romero-Graillet et al, 1996; Schallreuter and Wood,
1999; Scherer-Opplinger et al, 1999), it remains to be investigated
how signaling activity of ANP and CNP by cGMP is operational in
unpigmented melanoma cells. In this context, it should be noted
that human melanoma cells often fail to produce melanin despite
having abundant tyrosinase protein due to the absence of protein
kinase C-b (PKC-b) (Park et al, 1993), which mediates
phosphorylation of the cytoplasmic domain of the tyrosinase for
pigmentation (Park et al, 1999). It is not clear, however, whether
activation of membrane-bound GCs by ANP and CNP leads to
direct involvement of cGMP-mediated phosphorylation of the
tyrosinase or is indirectly connected with the PKC-b pathway.
In conclusion, this is the ®rst in vitro study to analyze the
differences in cGMP formation in nonmetastatic and metastatic
melanoma cell lines compared with normal melanocytes in culture.
Here we report that (i) sGC is an important target for the signaling
activities of NO in melanocytic cells and (ii) absence of NO-
sensitive GC but upregulated activities of natriuretic-peptide-
sensitive membrane-bound GC isoforms are associated with the
metastasis of melanoma.
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